Arcus Biosciences (RCUS) Misses Q1 EPS by 17c

Arcus Biosciences (NYSE: RCUS) reported Q1 EPS of ($1.02), $0.17 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $17 million versus the consensus estimate of $31.61 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• JPMorgan Starts Computer Age Management Services (CAMS:IN ) at Overweight
• JPMorgan Starts Nippon Life India Asset Management Ltd (NAM:IN) at Overweight